

- 22 ^hDépartement de Microbiologie, Infectiologie et Immunologie, Université de Montréal,
23 Montreal, Quebec, Canada
- 24 ⁱCentre de Recherche du CHUM, Montreal, Quebec, Canada
- 25 ^jNational Reference Centre for Parasitology, Montreal, Quebec, Canada
- 26 ^kJ.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Quebec, Canada
- 27 † These authors contributed equally to this manuscript
- 28 Running Title: Evaluation of cPass SARS-CoV-2 assay
- 29 Tables: 2
- 30 Figures: 4
- 31 Word count text: 3119
- 32 Word count abstract: 219

33 *Funding*

34 C.P.Y and J. Papenburg hold a “Chercheur-boursier clinicien” career award from the Fonds de
35 recherche du Québec – Santé (FRQS). This work was partially supported by le Ministère de
36 l’Économie et de l’Innovation du Québec (Program de soutien aux organismes de recherche et
37 d’innovation), by the Fondation du CHUM, and by the Canadian Institutes of Health Research
38 (via the COVID-19 Immunity Task Force) to A.F. A.F. is the recipient of a Canada Research
39 Chair on Retroviral Entry (RCHS0235 950-232424). G.B.B, and J. Prévost are supported by
40 CIHR fellowships. R.G. is supported by a MITACS Accélération postdoctoral fellowship.
41 cPass kits were provided in kind by Genscript.

42 The funders had no role in study design, data collection and analysis, decision to publish, or
43 preparation of the manuscript.

44

45 *Potential conflicts of interest*

46 J. Papenburg reports grants from MedImmune, grants from Sanofi Pasteur, grants and personal fees
47 from Seegene, grants and personal fees from Janssen Pharmaceutical, grants and personal fees from
48 AbbVie, outside the submitted work. MPC reports personal fees from GEn1E Lifesciences (as a
49 member of the scientific advisory board) and personal fees from nplex biosciences (as a member of
50 the scientific advisory board), both outside the submitted work.

51

52 #Correspondence to:

53 Cédric Yansouni, MD, J.D. MacLean Centre for Tropical Diseases, Divisions of Infectious
54 Diseases and Medical Microbiology, McGill University Health Centre, 1001 Décarie Blvd.,
55 Room EM3.3242, Montreal, Qc., Canada H4A 3J1, Email: cedric.yansouni@mcgill.ca

56 **ABSTRACT**

57 **Background:** SARS-CoV-2 surrogate neutralization assays that obviate the need for viral
58 culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2
59 Neutralization Antibody Detection Kit (Genscript) is the first such commercially available
60 assay, detecting antibodies that block RBD/ACE-2 interaction. We aimed to evaluate cPass to
61 inform its use and assess its added value compared to anti-RBD ELISA assays.

62 **Methods:** Serum reference panels comprising 205 specimens were used to compare cPass to
63 plaque-reduction neutralization test (PRNT) and a pseudotyped lentiviral neutralization
64 (PLV) assay for detection of neutralizing antibodies. We assessed the correlation of cPass
65 with an ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and
66 across intervals from onset of symptoms of SARS-CoV-2 infection.

67 **Results:** Compared to PRNT-50, cPass sensitivity ranged from 77% - 100% and specificity
68 was 95% - 100%. Sensitivity was also high compared to the pseudotyped lentiviral
69 neutralization assay (93% [95%CI 85-97]), but specificity was lower (58% [95%CI 48-67]).
70 Highest agreement between cPass and ELISA was for anti-RBD IgG ($r=0.823$). Against the
71 pseudotyped lentiviral neutralization assay, anti-RBD IgG sensitivity (99% [95%CI 94-100])
72 was very similar to that of cPass, but overall specificity was lower (37% [95%CI 28-47]).
73 Against PRNT-50, results of cPass and anti-RBD IgG were nearly identical.

74 **Conclusions:** The added value of cPass compared to an IgG anti-RBD ELISA was modest.

75

76 Key Words: “SARS-CoV-2”, “COVID-19”, “Diagnosis”, “Serology”, “ELISA”,
77 “Neutralization Test”, “Neutralizing Antibodies”, “Immunity”

78

79 INTRODUCTION

80 Use cases for serological testing for prior exposure to *Severe acute respiratory*
81 *syndrome-related coronavirus-2* (SARS-CoV-2) have been reviewed in detail (1, 2). Despite a
82 rapid increase in the number and availability of serological assays detecting SARS-CoV-2
83 antibodies, critical knowledge gaps remain regarding the magnitude and kinetics of the
84 correlation between results of these assays and the presence of neutralizing antibodies.

85 Only a subset of antibodies against a specific antigen can neutralize viral replication.
86 Assays that measure neutralizing antibody levels, such as plaque reduction neutralization
87 tests (PRNT) and microneutralization methods, provide essential data; these assays can help
88 validate candidate diagnostic tests and define serological correlates of immunity. However,
89 functional cell-based assays of SARS-CoV-2 neutralization can only be performed in a
90 Biosafety Level 3 (BSL-3) laboratory, which is labour-intensive, costly, and severely limits
91 testing throughput. Pseudotyped viruses have been developed that incorporate the Spike
92 protein of SARS-CoV-2 and can be cultivated in BSL-2 conditions (3). Assays incorporating
93 such pseudotyped viruses provide a functional assessment of the host neutralizing antibody
94 responses as an alternative to using the wild-type virus (4-7). By contrast, surrogates of
95 neutralization that bypass the need for viral culture would offer substantial advantages in
96 terms of throughput, cost, and scalability. At least one direct ELISA assay detecting
97 antibodies to the whole Spike protein has received regulatory approval in Europe for
98 assessment of neutralizing antibodies (8). Further, several groups have proposed blocking
99 assays, leveraging different signal detection methods to quantify the presence of host
100 antibodies that can block the interaction of the SARS-CoV-2 Spike protein with human ACE-
101 2 receptor (9-12).

102 On 6 Nov 2020, the FDA issued an emergency use authorization (EUA) for the cPass
103 SARS-CoV-2 Neutralization Antibody Detection Kit (cPass; Genscript, Piscataway, NJ)(13),
104 which is the first such surrogate neutralization assay to be commercially available. The cPass
105 uses a blocking ELISA format with human ACE-2 receptor molecules coated on an ELISA
106 plate (9, 14). Human sera pre-incubated with labelled epitopes of the receptor binding
107 domain (RBD on S1 proteins) are then transferred to the plate. This blocking ELISA serves
108 as a surrogate assay to inform on the capacity of human sera to block the interaction between
109 the Spike fusion protein (through its RBD) and its cellular receptor ACE-2.

110 The objective of this study was to inform the use of the cPass and assess its added
111 value compared to laboratory-developed anti-RBD ELISA assays by performing an
112 evaluation using a variety of well characterised specimens. A number of reference panels
113 were utilized to better understand the ability of the cPass assay to detect significant titres of
114 neutralizing antibodies assessed by culture-based reference methods. We compared cPass to
115 PRNT and to a pseudotyped virus neutralization assay. We also sought to describe the
116 correlation of cPass with a laboratory-developed indirect ELISA detecting anti-RBD IgG,
117 IgM, and IgA antibodies at a single timepoint and across different timeframes among
118 specimens collected at a known interval from onset of symptoms of SARS-CoV-2 infection.

119 **METHODS**

120 **Ethics**

121 Research ethics board approval or exemption was obtained at all participating
122 institutions.

123 **Source of specimens tested**

124 We assembled several well-characterised SARS-CoV-2 serological specimen panels to
125 assess the performance characteristics of the cPass culture-free neutralization antibody
126 detection kit (Table 1). These panels included: a first panel from the Public Health Agency of
127 Canada’s National Microbiology Laboratory comprising serological samples from COVID-
128 19 patients, healthy individuals, as well as patients non-SARS-CoV-2 infections (NML panel
129 1; Supplemental Table 1); NML Panel 2 (the National SARS-CoV2 Serological Panel
130 (NSSP)), comprising 60 serum or plasma specimens from persons with prior SARS-CoV-2
131 infection documented by nucleic acid amplification testing (NAAT) and 21 specimens from
132 healthy blood donors collected in Canada prior to July 2019; the World Health
133 Organization’s “First WHO International Reference Panel for anti-SARS-CoV-2
134 immunoglobulin” (NIBSC code 20/268) (15); and two separate curated panels from Héma-
135 Québec and CR-CHUM. The later panels comprised convalescent plasma donors (confirmed
136 SARS-CoV-2 infection and complete resolution of symptoms for at least 14 days) with either
137 single timepoint or longitudinal follow-up. In addition to panels using neutralization assays as
138 the reference standard, we assembled 136 specimens from healthy blood donors who tested
139 negative for the presence of anti-SARS-CoV-2 antibodies by both a lab-developed anti-RBD
140 IgG ELISA and a commercial assay detecting anti-nucleocapsid antibodies (Abbott Architect
141 SARS-CoV-2 IgG Assay). These specimens, collected between 25 May and 9 July 2020,

142 were acquired to help assess the ability of the cPass assay to detect specimens that test
143 negative by other serological methods.

144 **Culture-free neutralization antibody detection assay (cPass)**

145 All specimens and controls were processed according to the manufacturer's
146 instructions (including a 10X dilution factor of the primary specimen) and were tested in
147 triplicate. The percentage of inhibition calculation was based on the mean of OD for each
148 triplicate. A cut-off of 30% inhibition of RBD-ACE2 binding was used to determine the
149 presence of neutralizing antibodies, based on the manufacturer's instructions for use.

150 **Detection of neutralizing antibodies by culture-based reference methods**

151 Neutralizing antibodies were detected via either assessment of plaque reduction
152 neutralization titres using wild-type SARS-CoV-2, or by determining the neutralization half-
153 maximal inhibitory dilution (PLV ID50) or the neutralization 80% inhibitory dilution (PLV
154 ID80) of pseudotyped lentiviral vector (16).

155 Assessment of plaque-reduction neutralization using wild-type SARS-CoV-2 was
156 performed at the Public Health Agency of Canada's National Reference Laboratory for
157 Microbiology. Briefly, serological specimens were diluted 2-fold from 1:20 to 1:640 in
158 DMEM supplemented with 2% FBS and challenged with 50 plaque forming units (PFU) of
159 SARS-CoV-2 (hCoV-19/Canada/ON_ON-VIDO-01-2/2020, EPI_-ISL_425177), which were
160 titrated by plaque assay (17). After 1 hour of incubation at 37°C and 5% CO₂, the sera-virus
161 mixtures were added to 12-well plates containing Vero E6 cells at 90% to 100% confluence
162 and incubated at 37°C and 5% CO₂ for 1 hour. After adsorption, a liquid overlay comprising
163 1.5% carboxymethylcellulose diluted in MEM supplemented with 4% FBS, L-glutamine,
164 non-essential amino acids, and sodium bicarbonate was added to each well and plates were

165 incubated at 37°C and 5% CO₂ for 72 hours. The liquid overlay was removed, and cells were
166 fixed with 10% neutral-buffered formalin for 1 hour at room temperature. The monolayers
167 were stained with 0.5% crystal violet for 10 minutes and washed with 20% ethanol. Plaques
168 were enumerated and compared to controls. The highest serum dilution resulting in 50% and
169 90% reduction in plaques compared with controls were defined as the PRNT-50 and PRNT-
170 90 endpoint titres, respectively. PRNT-50 titres and PRNT-90 titres $\geq 1:20$ were considered
171 positive for SARS-CoV-2 neutralizing antibodies.

172 Pseudoviral neutralization testing was performed as previously described (16).
173 Briefly, target cells were infected with single-round luciferase-expressing lentiviral particles.
174 HEK 293T cells were transfected by the calcium phosphate method with the lentiviral vector
175 pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for SARS- CoV-2
176 Spike at a ratio of 5:4. Two days post-transfection, cell supernatants were harvested and
177 stored at -80°C until use. 293T-ACE2 target cells were seeded at a density of 1×10^4
178 cells/well in 96-well luminometer-compatible tissue culture plates (Perkin Elmer) 24h before
179 infection. Recombinant viruses in a final volume of 100 μ L were incubated with the indicated
180 sera dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to
181 the target cells followed by incubation for 48h at 37°C; cells were lysed by the addition of 30
182 μ L of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar
183 luminometer (Berthold Technologies) was used to measure the luciferase activity of each
184 well after the addition of 100 μ L of luciferin buffer (15mM MgSO₄, 15mM KPO₄ [pH 7.8],
185 1mM ATP, and 1mM dithiothreitol) and 50 μ L of 1mM d-luciferin potassium salt
186 (ThermoFisher Scientific). The neutralization half-maximal inhibitory dilution (ID₅₀) or the
187 neutralization 80% inhibitory dilution (ID₈₀) represents the sera dilution to inhibit 50% or
188 80% of the infection of 293T-ACE2 cells by recombinant viruses bearing the indicated
189 surface glycoproteins.

190 **Indirect anti-RBD ELISA assays**

191 Specimens were analysed with a laboratory-developed indirect ELISA detecting anti-
192 RBD IgG, IgM, and IgA as previously described (16, 18).

193 **Statistical analysis**

194 The diagnostic accuracy of the cPass surrogate viral neutralization assay was
195 estimated compared to different reference standards (WT PRNT-50; WT PRNT-90; PLV
196 ID50; PLV ID80, Live Virus (CPE), and VSV-PV). Sensitivities and specificities are
197 presented with 95% confidence intervals (95% CI). The effect of varying the cut-off value
198 (i.e., % inhibition of RBD-ACE2 binding) for cPass positivity on the diagnostic accuracy of
199 the cPass against a PLV PRNT-50 reference standard was investigated using a receiver
200 operating characteristic (ROC) curve. The association between cPass % inhibition and results
201 obtained using laboratory-developed ELISA detecting anti-S-RBD IgG, IgM, and IgA are
202 presented in scatterplots with the strength of these associations informed by Pearson
203 correlation. Lastly, among specimens from individuals with a known interval from onset of
204 SARS-CoV-2 infection symptoms and repeated testing over time, spaghetti plots were
205 created to investigate any change in signal over time for the cPass and direct anti-S-RBD
206 ELISA with statistical significance assessed using the Wilcoxon matched-pairs signed-rank
207 test ($p < 0.05$ denoted by *). Statistical analyses were performed using R version 3.5.2 (R Core
208 Team, Vienna, Austria).

209

210 **RESULTS**

211 **Diagnostic accuracy for the detection of anti-SARS-CoV-2 neutralizing antibodies, and**
212 **the impact of using different reference standards**

213 Table 1 shows the estimated diagnostic accuracy of the GenScript cPass neutralization
214 antibody detection assay among well characterised specimen panels, according to different
215 reference standards. Among various reference standards, results from the same PLV ID50
216 assay were available for all panels except the WHO panel, and this was used to estimate
217 aggregate diagnostic accuracy values across several panels.

218 Overall, cPass had sensitivity ranging 77% - 100% and specificity of 95% - 100%
219 compared to the reference standard of a 50% plaque reduction neutralization using SARS-
220 CoV-2 viral culture (WT PRNT-50) (Table 1). Changing the WT PRNT-50 cut-off titre from
221 1:20 to 1:50 had minimal impact on specimen categorization. Sensitivity remained very high
222 compared to the reference standard of a neutralization half-maximal inhibitory dilution using
223 a validated pseudotyped lentiviral vector neutralization assay (PLV ID50) with a cut-off titre
224 of 1:50, but specificity was lower than that compared to WT PRNT-50, ranging from 17-70%
225 (Table 1).

226 The effect of cut-off values on the diagnostic accuracy of the GenScript cPass assay is
227 shown in Figure 1. A receiver operating characteristic (ROC) curve using the reference
228 standard of PLV ID50 yielded an area under the ROC curve of 0.858.

229 **Effect of serial dilution on the accuracy for detecting sera with positive PRNT-90 titres**

230 Against the most stringent reference standard of 90% plaque reduction neutralization
231 using SARS-CoV-2 viral culture (WT PRNT-90), estimated specificity was reduced
232 compared to WT PRNT-50. Specificity remained similar whether a cut-off WT PRNT-90
233 titre for positivity of 1:20 or 1:50 was used [61% (95%CI 42-77) and 57% (95%CI 39-74),
234 respectively] (Table 1). We performed serial dilution of the 16 primary specimens from the
235 National Microbiology Laboratory Panel with WT PRNT-50 titres $\geq 1:20$ to determine
236 whether we could establish a dilution that increased specificity for detecting those with WT

237 PRNT-90 titres $\geq 1:20$ without sacrificing sensitivity (Figure 2). A 50-fold dilution of
238 specimens with positive WT PRNT-50 titres increased specificity for those with positive WT
239 PRNT-90 titres from 11% (95% CI 0-48) to 100% (95% CI 66-100), with one missed PRNT-
240 90 positive specimen.

241 **Agreement of the GenScript cPass assay with laboratory-developed ELISA detecting**
242 **anti-RBD IgG, IgM, and IgA.**

243 Results obtained with cPass were compared to those obtained using laboratory-
244 developed ELISA detecting anti-RBD IgG, IgM, and IgA to assess whether the cPass yields
245 complementary information (Figure 3). Highest agreement between cPass percent inhibition
246 of RBD-ACE2 binding and ELISA readout was seen for anti-RBD IgG (Pearson correlation
247 coefficient $r=0.823$), compared to that observed with anti-RBD IgM and IgA ($r=0.505$ and
248 0.489 , respectively). The diagnostic accuracy of categorical anti-RBD IgG results for the
249 detection of SARS-CoV-2 neutralizing antibodies was very similar to that observed with the
250 cPass for most panels and reference standards (Tables 1 and 2). Compared to PLV ID50,
251 cPass overall sensitivity was 93% [95% CI 85-97] and specificity 58% [95% CI 48-67],
252 whereas anti-RBD IgG overall sensitivity was 99% [95% CI 94-100] and specificity 37%
253 [95% CI 28-47].

254 However, when NML panel 2 was considered in isolation, categorical results for the
255 detection of SARS-CoV-2 neutralizing antibodies differed substantially between cPass and
256 anti-RBD IgG in terms of sensitivity compared to WT PRNT-50 (cPass 77% [95% CI 64-87],
257 anti-RBD IgG 98% [95% CI 91-100]) and specificity compared to PLV ID50 (cPass 61%
258 [95% CI 47-74], anti-RBD IgG 39% [95% CI 26-53]). If a cut-off of 20% RBD-ACE2
259 binding inhibition were used instead of the 30% cut-off recommended by the manufacturer,

260 cPass sensitivity against WT PRNT-50 would rise to 92% [95% CI 82-97] with a lower
261 estimated specificity of 46% [95% CI 33-60].

262 Among paired specimens from the same individual collected at a known interval from
263 SARS-CoV-2 diagnosis, aggregate results of both cPass and direct anti-RBD IgG ELISA did
264 not change between 6 weeks and 10 weeks after diagnosis ($p=1.00$ and 0.104 , respectively,
265 by the Wilcoxon signed rank test) (Figure 4). In contrast, ELISA readouts decreased
266 significantly over the same timeframe for direct anti-RBD IgM ($p=0.0058$) and IgA
267 ($p=0.0012$).

268 **Negative agreement between cPass and other serological assays.**

269 Among 136 specimens from healthy blood donors who tested negative for the presence
270 of anti-SARS-CoV-2 antibodies by both a lab-developed anti-RBD IgG ELISA and the
271 Abbott Architect SARS-CoV-2 IgG Assay (anti-N protein), cPass yielded negative results for
272 134 specimens (negative agreement 98.5% [95% CI 94.8 – 99.8]).

273 **DISCUSSION**

274 Rapid and high throughput surrogates for PRNT or pseudovirus neutralization assays
275 that bypass the need for cell culture are awaited with the belief that they will offer additional
276 information to that from standard direct immunoassays, such as a higher specificity for
277 neutralizing antibodies. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit
278 (cPass) is the first such assay to be commercially available and to receive FDA EUA in the
279 U.S. An evaluation of a cPass prototype, using a cut-off value of 20% inhibition, found that it
280 could provide a high-throughput screening tool for confirmatory PRNT testing (19). The
281 results of the current evaluation support the ability for cPass to detect neutralizing antibodies
282 to SARS-CoV-2, although specificity varied considerably depending on the reference assay
283 used. Our data also extend these findings by showing that cPass performed similarly to a non-
284 blocking anti-RBD ELISA among varied well characterised specimen panels.

285 Among 205 specimens evaluated by a SARS-CoV-2 reference neutralization assay in
286 the current work - either WT PRNT-50 or PLV ID50 - the overall estimated sensitivity of
287 cPass for detection of anti-SARS-CoV-2 neutralizing antibodies was high, regardless of the
288 reference standard technique or reference standard cut-off titre for positivity. The lower
289 sensitivity of cPass compared to WT PRNT-50 observed for specimens in NML panel 2
290 (Table 1) appears related to the choice of 30% RBD-ACE2 binding inhibition cut-off
291 recommended by the manufacturer, which may result in false negative results for specimens
292 with low titres of neutralizing antibodies. Among all specimens evaluated, however, reducing
293 the inhibition cut-off to 20% would have a minimal impact on overall sensitivity and yield
294 substantial reduction in overall specificity compared to PLV-50 (Figure 1). Our results do not
295 suggest that the cPass assay, targeting only RBD-ACE2 blockade, would miss a substantial
296 proportion of patients with neutralizing antibodies that target non-RBD epitopes (20-22). This

297 may be because neutralizing antibodies to non-RBD epitopes usually occur concomitantly
298 with anti-RDB neutralizing antibodies, instead of in isolation.

299 By contrast, estimates of the specificity of cPass for the detection of anti-SARS-CoV-
300 2 neutralizing antibodies were contingent of the reference standard used (Table 1). There was
301 near-perfect negative agreement with WT PRNT-50 using a cut-off titre of either 1:20 or
302 1:50. However, negative agreement was much lower when cPass was compared to either
303 PLV ID50 or WT PRNT-90. Our data raise the unresolved questions of which reference
304 technique (i.e., wild-type or pseudotyped live viral culture), level of stringency (e.g., 50%
305 inhibition of infection vs 80%, 90%, etc), and cut-off titre (e.g., 1:20 vs 1:50) best represent
306 serocorrelates of protection to SARS-CoV-2, or other relevant applications. Moreover,
307 protocols can vary widely for the same technique across different laboratories, requiring
308 caution in the interpretation of these and other data (23). In the current manuscript, PLV ID50
309 with a cut-off titre of 1:50 was used as the overall comparator because it was the technique
310 applied to all available specimen panels except the 5-member panel from WHO. Our results
311 must be interpreted in context with this potential source of bias. However, we note that this
312 technique has been employed by other groups and thus offers a high degree of
313 generalizability with other results (24, 25).

314 The cPass assay detected all specimens with positive WT PRNT-90 titres, with a
315 significant proportion of false positives (Figure 2). A 50-fold dilution of the 16 primary
316 specimens with WT PRNT-50 titres $\geq 1:20$ increased specificity for detecting those with WT
317 PRNT-90 titres $\geq 1:20$ from 11% (95% CI 0-48) to 100% (95% CI 66-100). This may
318 represent a useful approach for using the cPass assay to identify blood specimens with
319 positive WT PRNT-90 titres, which has been proposed as a desirable characteristic for sera
320 used in convalescent plasma trials by some regulatory agencies.

321 Finally, results of the cPass assay are best correlated with those of a laboratory-
322 developed indirect anti-RBD ELISA detecting IgG, both at a single timepoint (Table 2,
323 Figure 3) and across time among paired specimens from the same individual collected at a
324 known interval from symptoms onset (Figure 4). However, a slightly higher specificity for
325 the detection of anti-SARS-CoV-2 neutralizing antibodies was observed for cPass compared
326 to anti-RBD IgG ELISA across most panels (Tables 1 and 2). The fact that results of cPass
327 and anti-RBD IgG remained stable between 6 and 10 weeks post-symptom onset, while
328 ELISA readouts decreased significantly over the same timeframe for anti-RBD IgM and IgA
329 is potentially concerning given recent work suggesting a major role of IgM and IgA in the
330 neutralizing activity of convalescent plasma against SARS-CoV-2 (18, 26-28). The observed
331 trend toward lower specificity of cPass at later timepoints among convalescent plasma donors
332 with longitudinal follow-up (i.e. [60% (95% CI 15-95)] at 6 weeks vs [17% (95% CI 0-64)] at
333 10 weeks) may thus be related to loss of neutralizing IgM (Table 1). Taken together, these
334 results suggest that a positive cPass result in the context of a remote infection may not
335 accurately predict the presence of neutralizing antibodies. In addition, specificity of the cPass
336 may be affected by the possibility that part of the inhibition of binding in the cPass assay
337 could be due to steric hindrance by the abundant anti-Spike antibodies of the IgG isotype
338 rather than by true neutralization (as occurs in vivo).

339

340 **CONCLUSIONS**

341 The results of the current evaluation demonstrate the ability of cPass to detect blood
342 specimens with anti-SARS-CoV-2 neutralizing antibodies. However, the added value of
343 cPass compared to an IgG anti-RBD ELISA was modest.

344 **ACKNOWLEDGEMENTS**

345 We thank the convalescent plasma donors who participated in this study; the Héma-
346 Québec team involved in convalescent donor recruitment and plasma collection; the staff
347 members of the CRCHUM BSL3 Platform for technical assistance; Stefan Pöhlmann (Georg-
348 August University, Germany) for the plasmid coding for SARS-CoV-2 S.

349 **REFERENCES**

350

- 351 1. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, Caya C,
352 Semret M, Quach C, Libman M, Mazzola L, Sacks JA, Dittrich S, Papenburg J. 2020.
353 Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A
354 Narrative Review. *Ann Intern Med* 173:450-460.
- 355 2. Van Caesele P, Bailey D, Forgie SE, Dingle TC, Kraiden M. 2020. SARS-CoV-2
356 (COVID-19) serology: implications for clinical practice, laboratory medicine and
357 public health. *Cmaj* 192:E973-e979.
- 358 3. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY,
359 Tortorici MA, Veessler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD.
360 2020. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2
361 Spike Protein for Neutralization Assays. *Viruses* 12.
- 362 4. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li
363 X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and
364 validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg Microbes*
365 *Infect* 9:680-686.
- 366 5. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,
367 Jiang K, Arunkumar GA, Jurczynszak D, Polanco J, Bermudez-Gonzalez M, Kleiner
368 G, Aydilillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH,
369 Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng
370 AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020. A
371 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*
372 26:1033-1036.

- 373 6. Li Q, Liu Q, Huang W, Li X, Wang Y. 2018. Current status on the development of
374 pseudoviruses for enveloped viruses. *Rev Med Virol* 28.
- 375 7. Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, Manenti A,
376 Montomoli E. 2020. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and
377 Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based
378 Micro Neutralisation Assays. *Viruses* 12.
- 379 8. DiaSorin S.p.A. 2020. Liaison(R) SARS-CoV-2 S1/S2 IgG Brochure -A quantitative
380 assay with correlation to neutralizing antibodies.6.
- 381 9. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia
382 WR, Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. 2020. A SARS-CoV-2
383 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-
384 spike protein-protein interaction. *Nat Biotechnol* 38:1073-1078.
- 385 10. Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X,
386 Shi PY. 2020. A high-throughput neutralizing antibody assay for COVID-19
387 diagnosis and vaccine evaluation. *Nat Commun* 11:4059.
- 388 11. Danh K, Karp DG, Robinson PV, Seftel D, Stone M, Simmons G, Bagri A,
389 Schreibman M, Buser A, Holbro A, Battegay M, Corash LM, Hanson C, Tsai CT.
390 2020. Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay.
391 medRxiv doi:10.1101/2020.05.28.20105692.
- 392 12. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budyłowski
393 P, Dupuis AP, 2nd, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K,
394 McGeer AJ, Mubareka S, Gommerman JL, Durocher Y, Ostrowski M, McDonough
395 KA, Drebot MA, Drews SJ, Rini JM, Gingras AC. 2020. A simple protein-based
396 surrogate neutralization assay for SARS-CoV-2. *JCI Insight* 5.

- 397 13. U.S. Food and Drug Administration (FDA). 2020. Coronavirus (COVID-19) Update:
398 FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior
399 SARS-CoV-2 Infection.
- 400 14. GenScript USA Inc. 2020. cPass(TM) SARS-CoV-2 Neutralization Antibody
401 Detection Kit -Instructions for use.18.
- 402 15. The National Institute for Biological Standards and Control (NIBSC). 2020. First
403 WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (NIBSC
404 code: 20/268).2.
- 405 16. Prévost J, Gasser R, Beaudoin-Bussièrès G, Richard J, Duerr R, Laumaea A, Anand
406 SP, Goyette G, Benlarbi M, Ding S, Medjahed H, Lewin A, Perreault J, Tremblay T,
407 Gendron-Lepage G, Gauthier N, Carrier M, Marcoux D, Piché A, Lavoie M, Benoit
408 A, Loungnarath V, Brochu G, Haddad E, Stacey HD, Miller MS, Desforages M, Talbot
409 PJ, Maule GTG, Côté M, Therrien C, Serhir B, Bazin R, Roger M, Finzi A. 2020.
410 Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell*
411 *Rep Med* 1:100126.
- 412 17. Mendoza EJ, Manguiat K, Wood H, Drebot M. 2020. Two Detailed Plaque Assay
413 Protocols for the Quantification of Infectious SARS-CoV-2. *Curr Protoc Microbiol*
414 57:ecpmc105.
- 415 18. Beaudoin-Bussièrès G, Laumaea A, Anand SP, Prévost J, Gasser R, Goyette G,
416 Medjahed H, Perreault J, Tremblay T, Lewin A, Gokool L, Morrissette C, Bégin P,
417 Tremblay C, Martel-Laferrrière V, Kaufmann DE, Richard J, Bazin R, Finzi A. 2020.
418 Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent
419 Individuals. *mBio* 11:e02590-20.
- 420 19. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C,
421 Lamoureux L, McLachlan E, Schiffman Z, Drebot MA, Wood H. 2020. Evaluation of

- 422 a commercially-available surrogate virus neutralization test for severe acute
423 respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis*
424 99:115294.
- 425 20. Voss WN, Hou YJ, Johnson NV, Kim JE, Delidakis G, Horton AP, Bartzoka F, Paresi
426 CJ, Tanno Y, Abbasi SA, Pickens W, George K, Boutz DR, Towers DM, McDaniel
427 JR, Billick D, Goike J, Rowe L, Batra D, Pohl J, Lee J, Gangappa S, Sambhara S,
428 Gadush M, Wang N, Person MD, Iverson BL, Gollihar JD, Dye J, Herbert A, Baric
429 RS, McLellan JS, Georgiou G, Lavinder JJ, Ippolito GC. 2020. Prevalent, protective,
430 and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-
431 19 convalescent plasma. *bioRxiv* doi:10.1101/2020.12.20.423708.
- 432 21. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, Jangra RK,
433 Dieterle ME, Lilov A, Huang D, Tse LV, Johnson NV, Hsieh C-L, Wang N, Nett JH,
434 Champney E, Burnina I, Brown M, Lin S, Sinclair M, Johnson C, Pudi S, Bortz R,
435 3rd, Wirchnianski AS, Lauder Milch E, Florez C, Fels JM, O'Brien CM, Graham BS,
436 Nemazee D, Burton DR, Baric RS, Voss JE, Chandran K, Dye JM, McLellan JS,
437 Walker LM. 2020. Broad neutralization of SARS-related viruses by human
438 monoclonal antibodies. *Science (New York, NY)* 369:731-736.
- 439 22. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa
440 A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD,
441 Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. 2020. Potent
442 neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*
443 584:450-456.
- 444 23. Ferrara F, Temperton N. 2018. Pseudotype Neutralization Assays: From Laboratory
445 Bench to Data Analysis. *Methods Protoc* 1.

- 446 24. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J,
447 Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatzioannou T,
448 Jenks S, Bieniasz PD. 2020. Longitudinal Serological Analysis and Neutralizing
449 Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. *The Journal of*
450 *Infectious Diseases* doi:10.1093/infdis/jiaa659.
- 451 25. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Ladinsky M,
452 Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes
453 CO, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum
454 Y, Jha D, Tankelevich M, Yee J, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A,
455 Hatzioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig
456 MC. 2020. Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv*
457 doi:10.1101/2020.11.03.367391:2020.11.03.367391.
- 458 26. Gasser R, Cloutier M, Prévost J, Corby F, Ducas E, Ding S, Dussault N, Landry P,
459 Tremblay T, Laforce-Lavoie A, Lewin A, Beaudoin-Bussièrès G, Laumaea A,
460 Medjahed H, Larochelle C, Richard J, Dekaban G, Dikeakos J, Bazin R, Finzi A.
461 2020. Major role of IgM in the neutralizing activity of convalescent plasma against
462 SARS-CoV-2. *Cell Rep*, in press doi:<https://doi.org/10.1101/2020.10.09.333278>.
- 463 27. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT,
464 Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoeber
465 J, Jurczynszak D, Bermudez-Gonzalez M, Nádas A, Liu S, Lee B, Zolla-Pazner S, Hioe
466 CE. 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J*
467 *Infect Dis* doi:10.1093/infdis/jiaa784.
- 468 28. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J,
469 Devilliers H, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt CE,
470 Mayaux J, Beurton A, Fourati S, Bruel T, Schwartz O, Lacorte JM, Yssel H, Parizot

471 C, Dorgham K, Charneau P, Amoura Z, Gorochov G. 2020. IgA dominates the early
472 neutralizing antibody response to SARS-CoV-2. Sci Transl Med
473 doi:10.1126/scitranslmed.abd22223.
474

475 **TABLE 1.** Diagnostic accuracy of the GenScript cPass surrogate viral neutralization assay to
476 detect neutralizing antibodies among well-characterised specimen panels, according to
477 reference standard used

SOURCE	Number	Reference standard	Cut-off for reference positivity^a	TP	FP	FN	TN	Sensitivity % (95% CI)	Specificity % (95% CI)
National Microbiology Laboratory panel #1 (Canada)	20 SARS-CoV-2 PCR positive 20 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	19	1	0	20	100 (82-100)	95 (76-100)
			1:50	18	2	0	20	100 (81-100)	91 (71-99)
			1:20	7	13	0	20	100 (59-100)	61 (42-77)
			1:50	5	15	0	20	100 (48-100)	57 (39-74)
			PLV ID50	12	8	1	19	92 (64-100)	70 (50-86)
National Microbiology Laboratory panel #2 (Canada)	60 SARS-CoV-2 PCR positive 21 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	46	0	14	21	77 (64-87)	100 (84-100)
			1:50	45	1	13	22	78 (65-87)	96 (78-100)
			PLV ID50	24	22	1	34	96 (80-100)	61 (47-74)
WHO panel (UK)	3 SARS-CoV-2 positive 2 SARS-CoV-2 negative	WT PRNT-50	1:20	2	1	0	2	100 (16-100)	67 (9-99)
			1:20	3	0	1	1	75 (19-99)	100 (3-100)
			VSV-PV	3	0	0	2	100 (29-100)	100 (16-100)

HQ Blood bank -convalescent plasma donors with longitudinal follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50 15 Patients, 6 weeks post-symptom onset	PLV ID50	1:50	10	2	0	3	100 (69- 100)	60 (15-95)
	Specimens characterised by anti-S-RBD ELISA and PLV ID50 14 Patients, 10 weeks post- symptom onset	PLV ID50	1:50	8	5	0	1	100 (63- 100)	17 (0-64)
HQ Blood bank -convalescent plasma donors with single timepoint follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50 50 Patients, any time post-symptom onset	PLV ID50	1:50	24	12	4	10	86 (67-96)	45 (24-68)
	0-6 weeks post-symptom onset			11	6	1	0	92 (62- 100)	0 (0-46)
	>6 weeks post-symptom onset			13	6	3	10	81 (54-96)	62 (35-85)
Overall (vs PLV ID50)^c		PLV ID50	1:50	78	49	6	67	93 (85-97)	58 (48-67)

478 ^a Cut-off used to determine cPass positivity was $\geq 30\%$ inhibition

479 ^b From patients meeting public health case definitions of COVID-19, with either NAAT-confirmed SARS CoV-2
480 infection or an epidemiological link to a known case of COVID-19 (SARS CoV-2 infection).

481 ^c Results from the same PLV ID50 neutralization assay were available for all panels except the WHO panel; PLV
482 ID50 assay was used to calculate overall diagnostic accuracy values.

483

484 WT PRNT-50 or PRNT-90 denotes neutralization titres required for a 50% or 90% plaque reduction, respectively,
485 using SARS-CoV-2 viral culture; PLV ID50 or PLV ID80 denotes the serum dilution to inhibit 50% or 80% of the
486 infection of 293T-ACE2 cells by recombinant viruses bearing the indicated surface glycoproteins; TP true
487 positive; FP false positive; FN false negative; TN true negative; Anti-S-RBD antibodies against receptor binding
488 domain of SARS-CoV-2 Spike protein; HQ Héma-Québec; WHO World Health Organization; VSV PV Vesicular
489 stomatitis virus pseudovirus; CPE cytopathic effect; NAAT nucleic acid amplification test.

490 **TABLE 2.** Diagnostic accuracy of a laboratory-developed IgG anti-RBD ELISA to detect
491 neutralizing antibodies
492

SOURCE	Number	Reference standard	Cut-off for positivity^a	TP	FP	FN	TN	Sensitivity	Specificity
National Microbiology Laboratory panel #1 (Canada)	20 SARS-CoV-2 positive 20 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	19	1	0	20	100 (82-100)	95 (76-100)
			1:50	18	2	0	20	100 (81-100)	91 (71-99)
		WT PRNT-90	1:20	7	13	0	20	100 (59-100)	61 (42-77)
			1:50	5	15	0	20	100 (48-100)	57 (39-74)
		PLV PRNT-50	1:50	12	8	1	19	92 (64-100)	70 (50-86)
			PLV ID80	1:50	10	10	0	20	100 (69-100)
National Microbiology Laboratory panel #2 (Canada)	60 SARS-CoV-2 PCR positive 21 negative for SARS-CoV-2 and positive for related infections	WT PRNT-50	1:20	59	0	1	21	98 (91-100)	100 (84-100)
			1:50	57	2	1	21	98 (91-100)	91 (72-99)
			PLV ID50	1:50	25	34	0	22	100 (86-100)

HQ Blood bank - convalescent plasma donors with longitudinal follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50 15 Patients, 6 weeks post-symptom onset	PLV ID50	1:50	10	3	0	2	100 (69-100)	40 (5-85)
	Specimens characterised by anti-S-RBD ELISA and PLV ID50 14 Patients, 10 weeks post-symptom onset	PLV ID50	1:50	8	6	0	0	100 (63-100)	0 (0-46)
HQ Blood bank - convalescent plasma donors with single timepoint follow-up ^b	Specimens characterised by anti-S-RBD ELISA and PLV ID50 50 Patients, any time post-symptom onset	PLV ID50	1:50	28	22	0	0	100 (88-100)	0 (0-15)
	0-6 weeks post-symptom onset			12	6	0	0	100 (74-100)	0 (0-46)
	>6 weeks post-symptom onset			16	16	0	0	100 (79-100)	0 (0-21)
Overall (vs PLV ID50)			1:50	83	73	1	43	99 (94-100)	37 (28-47)

493 ^a Cut-off used to determine IgG anti-RBD ELISA positivity was ≥ 4.335 .

494

495 WT PRNT-50 or PRNT-90 denotes neutralization titres required for a 50% or 90% plaque reduction, respectively,

496 using SARS-CoV-2 viral culture; TP true positive; FP false positive; FN false negative; TN true negative; Anti-S-

497 RBD antibodies against receptor binding domain of SARS-CoV-2 Spike protein; HQ Héma-Québec; VSV PV

498 Vesicular stomatitis virus pseudovirus; CPE cytopathic effect.

499 **FIGURE LEGENDS**

500 **Figure 1.** Effect of cut-off values on the diagnostic accuracy of the Genscript cPass SARS-
501 CoV-2 neutralization antibody detection kit.

502 Panel (A) shows the receiver operating characteristic (ROC) curve, with different cPass cut-
503 offs. Panel (B) details results and estimates of sensitivity and specificity for different
504 %inhibition of RBD-ACE2 binding cut-offs for cPass positivity. The reference standard used
505 is PLV PRNT 50 at a titre of $\geq 1:50$. The specimens from the WHO panel (n=5) are not
506 included in the above figure as PLV PRNT 50 was not performed, thereby resulting in a total
507 N of 200. AUC denotes Area Under the ROC Curve; TP true positive; FP false positive; FN
508 false negative; TN true negative.

509

510 **Figure 2.** Effect of serial dilution on the accuracy for detecting sera with positive PRNT90
511 titres.

512 Serial dilution of the 16 primary specimens with WT PRNT 50 titres $\geq 1:20$ was performed to
513 establish a dilution that increased specificity for detecting those with WT PRNT 90 titres
514 $\geq 1:20$. Panel (A) shows individual data points according to dilution and WT PRNT 90 status
515 (positive $\geq 1:20$). Box plots depict the median and interquartile range. Panel (B) details results
516 and estimates of sensitivity and specificity for serial dilution factor. All dilution factors are
517 additional to the 10X dilution required in the manufacturer's instructions. WT PRNT 90
518 denotes neutralization titres required for a 90% plaque reduction using SARS-CoV-2 viral
519 culture; TP true positive; FP false positive; FN false negative; TN true negative.

520

521 **Figure 3.** Correlation of the Genscript cPass assay with anti-S-RBD ELISA.


522 Correlation of the Genscript cPass assay with the anti-S-RBD ELISA normalized relative
523 luciferase units (RLU) for each plasma tested at a dilution (1:500) is presented. Scatterplots

524 and Pearson correlation coefficient for results obtained with cPass compared to those
525 obtained using laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA (Panels
526 A, B, C, respectively). The vertical dashed line depicts the manufacturer's recommended cut-
527 off for cPass positivity. Specimens from the NML panel 2 and Héma-Québec convalescent
528 plasma donors panel are included in the above figure. Specimens from the NML panel #1
529 were excluded as anti-S-RBD ELISA for IgM and IgA were not performed.

530

531 **Figure 4.** Change of signal over time for Genscript cPass and anti-RBD ELISA.


532 Spaghetti plot of results obtained with cPass (panel A) and the plots shown in panels B, C, D
533 represent (B and C) the areas under the curve (AUC) calculated from relative luciferase units
534 (RLU) obtained with serial plasma dilutions or (D) the normalized RLU for one plasma
535 dilution (1:500) for laboratory-developed ELISA detecting anti-RBD IgG, IgM, and IgA
536 (panels B, C, D, respectively) among specimens collected at a known interval from SARS-
537 CoV-2 diagnosis. Horizontal lines indicate paired specimens form the same individual. P
538 values are calculated via the Wilcoxon signed rank test, and values <0.05 are designated with
539 an Asterix. In all panels, red dots denote specimens with positive cPass results, and blue dots
540 specimens with negative cPass results.



A

Threshold % inhibition for positivity	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
20%	80	64	4	52	95.2 (88.2-98.6)	44.8 (35.5-54.3)
30%	78	49	6	67	92.8 (85.0-97.3)	57.7 (48.2-66.8)
40%	72	36	12	80	85.7 (76.3-92.3)	68.9 (59.7-77.2)
50%	65	24	19	92	77.3 (66.9-85.7)	79.3 (70.7-86.2)
60%	54	15	30	101	64.2 (53.0-74.4)	87.0 (79.5-92.5)




B






A

Dilution Factor	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
1X	7	8	0	1	100 (59-100)	11 (0-48)
10X	7	3	0	6	100 (59-100)	67 (30-93)
50X	6	0	1	9	86 (42-100)	100 (66-100)
100X	4	0	3	9	57 (18-90)	100 (66-100)

B



A**B****C****D**